Health & Wealth: The Investors’ Guide to Antimicrobial Resistance (AMR), a Growing Global Health Crisis

Addressing AMR requires coordinated global efforts – and tackling this complex systemic risk presents both risks and opportunities for investors. By supporting sustainable business practices, whereby companies are supported to actively combat AMR, investors can contribute to global health solutions while mitigating financial risks associated with this growing crisis. Recognising the power of investors to influence pharmaceutical companies’ actions in global health specifically, the Access to Medicine Foundation works closely with these stakeholders to help drive change through its independent AMR Programme and the Investor Action on AMR initiative (IAAMR). 

In its capacity as a founding partner of the IAAMR, the Foundation has drawn on its analysis, insights and collaborative work with other founding partners and investor members to co-develop Health & Wealth: The Investors’ Guide to Antimicrobial Resistance (AMR), a growing global health crisis with MSCI Sustainability Institute. The aim of this guide is to help investors navigate the complexities of AMR, explore innovative investment opportunities, as well understand the value behind development of robust frameworks for addressing this global health challenge.  

Report highlights  

• Provides an overview of the current state of AMR 

• Outlines the systemic risk to investors and key investment considerations 

• Provides an analysis of potential AMR impacts, risks and opportunities by sub-industry 

• Assesses the impact of AMR on the economy, health, livestock and the environment 

• Summarises the current research and funding landscapes for novel antimicrobials 

• Outlines the economic case for investment in AMR solutions 

• Provides case studies from investors demonstrating how they are taking action on AMR